Olaratumab is a humanized IgG1 monoclonal antibody that blocks the platelet-derived growth factor receptor alpha (PDGFRα).
Soft tissue sarcoma represents about 1% of all solid malignancies. The standard chemotherapy regimens have included doxorubicin alone or in combination with other agents.
The National Institute for Health and Care Excellence (NICE) has published its Final Appraisal Determination on Lartruvo (olaratumab), from Eli...
The European Commission has granted an accelerated approval to olaratumab (Lartruvo) in combination with doxorubicin as a frontline therapy for...
The FDA has granted accelerated approval to Lartruvo (olaratumab), from Eli Lilly, with doxorubicin to treat adults with certain types...
Background: Trabectedin has recently been approved in the USA and in Europe for advanced soft-tissue sarcoma patients who have been treated with anthracycline-based chemotherapy without success.
Clear cell sarcoma is an aggressive soft tissue sarcoma and highly resistant to conventional chemotherapy and radiation therapy. This devastating disease is defined by EWSR1-ATF1 fusion gene resulting from chromosomal translocation...
Eli Lilly reported that the results of ANNOUNCE, the Phase III study of Lartruvo (olaratumab), in combination with doxorubicin in...
Soft tissue sarcomas (STS) represent a variety of tumors of mesenchymal origin, accounting for about 1% of all adult cancers. This group of tumors comprises over 60 different histotypes with different biology showing different sensitivity to therapeutic agents.
The FDA on 26 April 2012 approved Votrient (pazopanib)from Glaxo Smith Kline to treat patients with advanced Soft Tissue Sarcoma...